Live from the NIH registry
Studies recruiting near Fredericksburg right now
Top 25 of 36 recruiting studies, sorted by proximity — each links to its official registry page
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
Phase 3
Interventional 3,960 participants sought
Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: NRG Oncology
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer
Phase 2, Phase 3
Interventional 840 participants sought
Virginia Cancer Specialists, PC — Woodbridge, Virginia (27.9 mi)
· Sponsor: Pfizer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Phase 3
Interventional 1,210 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: National Cancer Institute (NCI)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Breast Cancer, Metastatic Breast Cancer
Phase 3
Interventional 404 participants sought
Hematology-Oncology Associates of Fredericksburg, Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: BriaCell Therapeutics Corporation
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,260 participants sought
Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)
Phase 3
Interventional 700 participants sought
Mary Washington Healthcare — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Incyte Corporation
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 3
Interventional 10,450 participants sought
Mary Washington Hospital — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Eli Lilly and Company
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Neoplasms, Head and Neck
Phase 3
Interventional 864 participants sought
GSK Investigational Site — Fredericksburg, Virginia (1.5 mi)
· Sponsor: GlaxoSmithKline
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Phase 3
Interventional 810 participants sought
Local Institution - 0297 — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Celgene
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2
Interventional 66 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: SWOG Cancer Research Network
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Overactive Bladder, Urinary Urgency Incontinence
N/A
Interventional 150 participants sought
Potomac Urology — Woodbridge, Virginia (27.9 mi)
· Sponsor: Axonics, Inc.
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Intestinal Neoplasms, Gastrointestinal Neoplasms
Phase 3
Interventional 800 participants sought
Virginia Cancer Specialists, PC — Woodbridge, Virginia (27.9 mi)
· Sponsor: Pfizer
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast Cancer, Cognitive Impairments
N/A
Interventional 386 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: NRG Oncology
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Phase 3
Interventional 320 participants sought
Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Chronic Kidney Disease and Hypertension
Phase 2
Interventional 218 participants sought
Research Site — Woodbridge, Virginia (27.9 mi)
· Sponsor: AstraZeneca
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
Phase 3
Interventional 675 participants sought
Hematology Oncology Associates of Fredericksburg ( Site 9550) — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Phase 3
Interventional 400 participants sought
Hematology Oncology Associates of Fredericksburg — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Celgene
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Phase 3
Interventional 2,500 participants sought
Anthos Investigational site 9817 — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Anthos Therapeutics, Inc.
Product Surveillance Registry
Cardiac Rhythm Disorders, Urological Disorders
N/A
Observational 100,000 participants sought
Research site — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Medtronic
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2
Interventional 56 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: SWOG Cancer Research Network
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Phase 3
Interventional 1,160 participants sought
Research Site — Fredericksburg, Virginia (1.5 mi)
· Sponsor: AstraZeneca
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia
Phase 3
Interventional 126 participants sought
Hematology Oncology Associates of Fredericksburg — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Amgen
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
Phase 3
Interventional 5,000 participants sought
Research Site — Woodbridge, Virginia (27.9 mi)
· Sponsor: AstraZeneca